Is There a Future for Anti-CD38 Antibody Therapy in Systemic Autoimmune Diseases?
CD38 is a type II glycoprotein highly expressed on plasmablasts, short-lived and long-lived plasma cells, but weakly expressed on other lymphoid cells, myeloid cells and non-hematopoietic cells. This expression pattern makes CD38 an interesting target for a targeted therapy aiming to deplete antibod...
Main Authors: | Devis Benfaremo, Armando Gabrielli |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-12-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/9/1/77 |
Similar Items
-
Increased expression of the ectoenzyme CD38 in peripheral blood plasmablasts and plasma cells of patients with systemic sclerosis
by: S. Agarbati, et al.
Published: (2022-12-01) -
Ekspresi CD3 dan CD26 pada Limfosit T sebagai Biomarker Potensial Penyakit Systemic Lupus Erythematosus
by: Yuliana Heri Suselo, et al.
Published: (2016-09-01) -
CD38 Is Robustly Induced in Human Macrophages and Monocytes in Inflammatory Conditions
by: Stephanie A. Amici, et al.
Published: (2018-07-01) -
Diagnosis of tuberculosis with autoimmune hepatitis–systemic lupus erythematosus overlap syndrome: a case report
by: Shekhar, et al.
Published: (2022-11-01) -
Zetomipzomib (KZR-616) attenuates lupus in mice via modulation of innate and adaptive immune responses
by: Tony Muchamuel, et al.
Published: (2023-03-01)